利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

3475 条记录 (耗时 0.029 秒)

    NOVEL G-CSF MIMICS AND THEIR APPLICATIONS
    34.
    发明公开
    NOVEL G-CSF MIMICS AND THEIR APPLICATIONS 审中-公开

    公开(公告)号：US20230227520A1

    公开(公告)日：2023-07-20

    申请号：US17757550

    申请日：2020-12-17

    申请人： Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. ,  Eberhard Karls Universität Tübingen

    发明人： Mohammad ELGAMACY ,  Birte HERNANDEZ ALVAREZ ,  Yulia SKOKOWA

    IPC分类号： C07K14/535 ,  C12N5/00 ,  A61P7/00 ,  A61K38/18

    CPC分类号： C07K14/535 ,  C12N5/0018 ,  A61P7/00 ,  A61K38/18

    摘要： The present invention relates to a protein having G-CSF-like activity comprising a) one or two polypeptide chains; b) a bundle of four α-helices; and c) two or three amino acid linkers that connect contiguous bundle-forming α-helices that are located on the same polypeptide chain, wherein each amino acid linker has a length between 2 and 20 amino acids. The invention also provides for a polynucleotide and a vector encoding the protein of the invention, host cells comprising said polynucleotide, a method for producing the protein of the invention and a pharmaceutical composition comprising the protein of the invention. The invention further relates to uses of the proteins of the invention as a research reagent and the use of the protein and/or pharmaceutical composition comprising the same as a medicament, e.g., for use in increasing stem cell production, for use in inducing hematopoiesis and/or for use in mobilizing hematopoietic stem cells.

    CIRCULATING B CELL SUBPOPULATIONS IN INDOLENT B CELL LYMPHOMA
    40.
    发明公开
    CIRCULATING B CELL SUBPOPULATIONS IN INDOLENT B CELL LYMPHOMA 审中-公开

    公开(公告)号：US20230181581A1

    公开(公告)日：2023-06-15

    申请号：US17924610

    申请日：2021-05-20

    申请人： Alexion Pharmaceuticals, Inc.

    发明人： Gregory Coffey ,  Matthew Birrell ,  Pamela B. Conley ,  Andreas H. Betz

    IPC分类号： A61K31/506 ,  G01N33/574 ,  A61P35/00 ,  A61P7/00

    CPC分类号： A61K31/506 ,  A61P7/00 ,  A61P35/00 ,  G01N33/57407

    摘要： Methods for treating B cell lymphomas are provided. B cell lymphomas patients suitable for treatments can be identified based on the baseline B cell subset frequencies. For instance, increased frequency of transitional (CD10+) B cells within total nave B cells or within total B cells predicts poor response to kinase inhibitors. By contrast, having an increased nave B cells to total B cells frequency without an increased transitional (CD10+) B cell frequency predicts good response to the kinase inhibitors. Having a decreased frequency of nave B cells of the total B cell population with a corresponding increase in frequency of memory switched and double negative B cells of the total B cell population also predicts good response to the kinase inhibitors. Once the patients are identified, the patients can be suitably treated with the kinase inhibitors such as cerdulatinib.